Hospital
Van Wert County Hospital Association
Van Wert County Hospital Association was paid $6.20M by Medicaid between Jan 2018 and Dec 2024, across 170 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoVAN WERT COUNTY HOSPITAL ASSOCIATION
VAN WERT, OH 45891
VAN WERT, OH 45891
33aNPI1942267760assigned 04/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.20M
24GClaims169,211
24DCodes billed170
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#85 of 101
Median peer was paid$22.32M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,314 | $240K | |
| 2019 | 7,964 | $265K | |
| 2020 | 6,579 | $313K | |
| 2021 | 8,253 | $405K | |
| 2022 | 9,650 | $429K | |
| 2023 | 87,146 | $2.47M | |
| 2024incomplete | 43,305 | $2.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 5,670 | 4,829 | $643K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10.0% | 5,047 | 4,075 | $620K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 4,967 | 3,673 | $590K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 4,435 | 3,870 | $470K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.4% | 6,555 | 2,325 | $461K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.4% | 5,009 | 1,367 | $395K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.1% | 1,029 | 690 | $319K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.7% | 1,237 | 908 | $291K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 4.3% | 2,863 | 1,185 | $264K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 948 | 704 | $261K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.2% | 4,041 | 1,629 | $258K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 1,440 | 1,330 | $156K |
158 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 2.1% | 1,461 | $130K |
| 80053 | Comprehensive metabolic panel | 1.4% | 11,000 | $88K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 375 | $86K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 744 | $81K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,828 | $58K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,386 | $51K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 832 | $41K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 215 | $38K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 635 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,234 | $37K |
| 73630 | <1% | 792 | $36K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,275 | $34K |
| 97162 | <1% | 454 | $31K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,457 | $30K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 214 | $30K |
| 87070 | <1% | 1,186 | $29K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 568 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,593 | $25K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,017 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,357 | $24K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,491 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,559 | $23K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 69 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 135 | $22K |
| 80061 | Lipid panel | <1% | 1,420 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,230 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 161 | $18K |
| 87631 | <1% | 100 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 635 | $17K |
| 84439 | <1% | 881 | $17K | |
| 93017 | <1% | 198 | $16K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 31 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 314 | $13K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,118 | $12K |
| 73610 | <1% | 301 | $12K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $11K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 408 | $11K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 81 | $11K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 226 | $9K |
| G0378 | Hospital observation service, per hour | <1% | 279 | $9K |
| 74018 | <1% | 179 | $9K | |
| 73130 | <1% | 254 | $9K | |
| 83735 | <1% | 1,935 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 337 | $8K |
| 85027 | <1% | 859 | $8K | |
| 87634 | <1% | 559 | $7K | |
| 86140 | <1% | 371 | $7K | |
| 97166 | <1% | 120 | $7K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 62 | $6K |
| 97161 | <1% | 65 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,377 | $6K |
| 82728 | <1% | 340 | $6K | |
| 82607 | <1% | 221 | $6K | |
| 72100 | <1% | 120 | $5K | |
| 64493 | <1% | 14 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 76 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,439 | $4K |
| 83540 | <1% | 381 | $4K | |
| 87400 | <1% | 200 | $4K | |
| 73562 | <1% | 133 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 312 | $4K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 86 | $4K |
| 86850 | <1% | 164 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 517 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 39 | $4K |
| 80076 | <1% | 437 | $4K | |
| 81003 | <1% | 1,037 | $3K | |
| 81001 | <1% | 3,171 | $3K | |
| 87186 | <1% | 511 | $3K | |
| 84484 | <1% | 2,533 | $3K | |
| 83550 | <1% | 290 | $3K | |
| J3490 | Unclassified drugs | <1% | 961 | $2K |
| 87088 | <1% | 369 | $2K | |
| 85610 | <1% | 1,513 | $2K | |
| 87077 | <1% | 246 | $2K | |
| 82043 | <1% | 266 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 310 | $2K |
| 86900 | <1% | 171 | $2K | |
| 73030 | <1% | 73 | $2K | |
| 73110 | <1% | 48 | $2K | |
| 84702 | <1% | 82 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,620 | $2K |
| 71250 | <1% | 16 | $1K | |
| 85651 | <1% | 314 | $1K | |
| 92523 | <1% | 12 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 82 | $1K |
| 93971 | <1% | 12 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 840 | $1K |
| 83880 | <1% | 780 | $1K | |
| 84100 | <1% | 355 | $1K | |
| 87205 | <1% | 127 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 261 | $1K |
| 82565 | <1% | 495 | $1K | |
| 83690 | <1% | 2,037 | $1K | |
| 82570 | <1% | 85 | $1K | |
| 59025 | Fetal non-stress test | <1% | 17 | $994.35 |
| 86901 | <1% | 172 | $980.29 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 52 | $954.82 |
| 80074 | <1% | 33 | $857.79 | |
| 86592 | <1% | 68 | $807.31 | |
| 83655 | <1% | 25 | $672.88 | |
| 85379 | <1% | 616 | $612.17 | |
| 83605 | <1% | 970 | $604.98 | |
| 94760 | <1% | 94 | $569.92 | |
| 84703 | <1% | 798 | $536.12 | |
| 84153 | <1% | 29 | $517.48 | |
| 82248 | <1% | 136 | $488.56 | |
| 73560 | <1% | 54 | $464.06 | |
| 82948 | <1% | 1,193 | $444.15 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,119 | $437.44 |
| 85730 | <1% | 751 | $429.88 | |
| 81025 | <1% | 792 | $382.38 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 59 | $379.50 |
| 85652 | <1% | 92 | $378.08 | |
| A9270 | Non-covered item or service | <1% | 3,346 | $337.37 |
| 82150 | <1% | 171 | $275.09 | |
| 86762 | <1% | 17 | $262.37 | |
| 84520 | <1% | 420 | $238.84 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,265 | $229.93 |
| 87040 | <1% | 548 | $216.77 | |
| 82077 | <1% | 175 | $152.10 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 324 | $151.90 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,045 | $129.97 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 505 | $102.74 |
| 80051 | <1% | 313 | $99.32 | |
| 80143 | <1% | 79 | $92.46 | |
| 82947 | <1% | 315 | $91.49 | |
| 96376 | <1% | 236 | $88.13 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 481 | $71.80 |
| 80179 | <1% | 79 | $67.81 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,021 | $64.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,193 | $53.23 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 368 | $51.56 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 277 | $45.52 |
| 82550 | <1% | 26 | $45.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,483 | $32.07 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 208 | $20.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 405 | $17.02 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,124 | $10.91 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 363 | $10.15 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 76 | $9.80 |
| 88304 | <1% | 25 | $9.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 899 | $5.43 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 314 | $5.19 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 36 | $2.52 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 764 | $1.53 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 68 | $0.45 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 78 | $0.01 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 59 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 32 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 83 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 69 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 14 | $0.00 |
| 84132 | 0% | 21 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 31 | $0.00 |
| 64494 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSILALAHI, EDGAR (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Van Wert County Hospital Association | Van Wert, OH | $37K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.